期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
白芍总苷治疗低度危险特发性膜性肾病的疗效及血清抗磷脂酶A2受体抗体在治疗中的意义 被引量:4
1
作者 唐琦 张黎明 +3 位作者 邬碧波 李林 俞华 梁从蝶 《药学服务与研究》 CAS 2018年第6期410-414,共5页
目的:观察白芍总苷(total glucosides of Radix paeoniae alba,TGP)治疗低度危险特发性膜性肾病(idiopathic membranous nephropathy,IMN)病人的疗效,并探讨血清抗磷脂酶A2受体(phospholipase A2receptor,PLA2R)抗体在治疗中的意义。方... 目的:观察白芍总苷(total glucosides of Radix paeoniae alba,TGP)治疗低度危险特发性膜性肾病(idiopathic membranous nephropathy,IMN)病人的疗效,并探讨血清抗磷脂酶A2受体(phospholipase A2receptor,PLA2R)抗体在治疗中的意义。方法:65例经肾活检确诊为低度危险IMN的病人(24h尿蛋白定量<4g且肾功能正常),根据血清抗PLA2R抗体检测结果分成4组,分别为抗PLA2R抗体阳性治疗组(A组,n=22)、抗PLA2R抗体阳性对照组(B组,n=22)、抗PLA2R抗体阴性治疗组(C组,n=10),以及抗PLA2R抗体阴性对照组(D组,n=11)。两组对照组采用保守治疗,两组治疗组在保守治疗基础上加用TGP 600mg/次,tid,治疗12个月。检测基线,治疗6、12个月后的24h尿蛋白、尿白蛋白与肌酐比值(ACR)、血白蛋白(SAlb)、血肌酐(SCr)、血清抗PLA2R抗体,并进行疗效及安全性评价。结果:65例病人中血清抗PLA2R抗体阳性病人44例,阳性率为67.7%。与同组基线和两个同期对照组比较,C组治疗6个月、12个月后,A组治疗12个月后,24h尿蛋白、ACR显著降低(P<0.05),SAlb显著升高(P<0.05)。治疗12个月后C组24h尿蛋白、ACR下降和SAlb升高比A组更显著(P<0.05)。治疗12个月后,两个治疗组(A组和C组)与两个对照组(B组和D组)比较有效率有统计学差异(66.7%vs 31%,P<0.01)。结论:TGF能有效减少低度危险IMN病人蛋白尿,提高临床疗效。与血清抗PLA2R抗体阳性组比较,血清抗PLA2R抗体阴性组治疗后蛋白尿和SAlb改善更显著。检测血清抗PLA2R抗体对低度危险IMN病人的治疗有参考价值。 展开更多
关键词 白芍总苷 肾脏病 特发性膜性 低度危险 抗磷脂酶A2受体抗体
下载PDF
The Role of Homocysteine and Other Clinical Laboratory Markers in Assessing Cardiovascular Risk in Patients on Hemodialysis
2
作者 Irena Ivanova Gencheva-Angelova Adelaida Lazarova Ruseva Pavlina Dimitrova Yordanova-Laleva 《Journal of Life Sciences》 2016年第1期48-53,共6页
Cardiovascular diseases constitute approximately 50% of deaths among dialysis patients in the USA and Europe. The increase in traditional and nontraditional cardiovascular risk factors in determining the high mortalit... Cardiovascular diseases constitute approximately 50% of deaths among dialysis patients in the USA and Europe. The increase in traditional and nontraditional cardiovascular risk factors in determining the high mortality of patients with end-stage renal disease (ESRD) is complicated due to the high frequency of risk factors in these patients. Some laboratory markers like homocysteine, albumin, cholesterol, triglycerides, LDL-cholesterol, and creatinine could be efficient in marking the risk of cardiovascular disease in these patients. We use Roche assay tests, based on routinely principles to determine this laboratory parameters used in the clinical laboratory. All laboratory parameters we measured on a biochemistry auto analyser Cobas Integra 400 at the clinical laboratory of University Hospital--Pleven. Using a statistical program a research was done on the quantitative characteristics and prognostic capabilities of homocysteine and other biochemical parameters. We determined the diagnostic specificity and sensitivity of our lab performance against vascular disease (heart attack or stroke) by ROC curves. For each of the observed values of biochemical parameters we calculated the diagnostic sensitivity and specificity. The threshold values for which the parameters have the highest sensitivity and specificity have been concluded. Summary of diagnostic value of parameters to judge the coefficient AUC--area under the curve, for cholesterol, LDL, triglycerides, albumin, it was a significant (P 〈 0.05). Homocysteine and the rest of the studied by us laboratory parameters can be regarded as laboratory markers of choice for assessing the risk of heart attack or stroke in patients on dialysis. 展开更多
关键词 HOMOCYSTEINE ALBUMIN end-stage renal disease cardiovascular risk factors.
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部